AUSAF (Australis Capital) ROE % Adjusted to Book Value: -38.64% (As of Dec. 2021)


What is Australis Capital ROE % Adjusted to Book Value?

Australis Capital AUSAF -95.00% ROE % Adjusted to Book Value is -38.64% as of Dec. 2021.

Australis Capital's ROE % for the quarter that ended in Dec. 2021 was -34.39%. Australis Capital's PB Ratio for the quarter that ended in Dec. 2021 was 0.89. Australis Capital's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2021 was -38.64%.

Australis Capital ROE % Adjusted to Book Value Related Terms

Australis Capital ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Australis Capital's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Australis Capital ROE % Adjusted to Book Value Chart

Australis Capital Annual Data
Trend Mar18 Mar19 Mar20 Mar21
ROE % Adjusted to Book Value
0.00 -8.95 -70.09 -38.11

Australis Capital Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -197.52 23.24 -51.40 -32.60 -38.64

AUSAF vs ZTS, CTLT, VTRS: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Australis Capital's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Australis Capital ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Australis Capital's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Australis Capital's ROE % Adjusted to Book Value falls into.


Australis Capital ROE % Adjusted to Book Value Calculation

Australis Capital's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2021 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-44.59% / 1.17
=-38.11%

Australis Capital's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2021 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-34.39% / 0.89
=-38.64%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -38.64% mean?
Australis Capital (AUSAF) has a ROE % Adjusted to Book Value of -38.64% as of Dec. 2021. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Australis Capital and its competitors.
Is Australis Capital's ROE % Adjusted to Book Value too high?
Australis Capital's current ROE % Adjusted to Book Value is -38.64%.
How does Australis Capital's ROE % Adjusted to Book Value compare to ZTS and CTLT?
Australis Capital's ROE % Adjusted to Book Value of -38.64% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Australis Capital and its competitors. Australis Capital's current ROE % Adjusted to Book Value is -38.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australis Capital stock overvalued right now?
Australis Capital (AUSAF) has a current ROE % Adjusted to Book Value of -38.64%. The current ROE % Adjusted to Book Value is -38.64%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Australis Capital (AUSAF), the current ROE % Adjusted to Book Value is -38.64% as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Australis Capital Business Description

Address 376 E. Warm Springs Road, Suite 190, Las Vegas, NV, USA, 89119
Australis Capital Inc operates as a multi-state operator in the cannabis industry in the US. The company is focused on brands and attractive cannabis licenses in states with favorable economics. AUSA is building an MSO based on a unique and very difficult to imitate strategy. Secure access to low-cost but high-quality biomass enables the company to fuel the expansion of its footprint across the US. The company has a rapidly growing footprint in the U.S. in states, such as California, Nevada, Massachusetts, Missouri, Oklahoma, as well as international operations through its subsidiary ALPS, with projects in Europe, Asia and North America.